New research reveals that semaglutide significantly improves liver health in MASH patients. A new study published in the New ...

Following completion of the dose escalation phase in relapsed/refractory acute leukemia patients with FLT3 mutations, Biomea ...

ROCKVILLE, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage ...

Thabo's eyes flicker as he steps into the familiar room of a clinic he has been visiting for as long as he can remember. He ...

Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat ...

VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial - - Closed a public offering on May 8, 2025, raising the Company's cash ...

A recent analysis reveals that ellipsoidal zone-retinal pigment epithelial thickness predicts future visual loss in ...

Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies ...

Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET. Company Participants. Jaclyn Jaffe - Senior Director, Corporate Operations Clau ...

Discover Compass Pathways' journey in developing COMP360 psilocybin for treatment-resistant depression, tackling regulatory ...

Advances in heart failure treatment have reduced hospitalizations by up to 30% and extended lives by years. Learn about ...

Operator: Ladies and gentlemen, thank you for standing by, and welcome. At this time all participants are in listen-only mode ...